Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Nov;32 Suppl 2(Suppl 2):S223-31.
doi: 10.2337/dc09-S315.

Incretin-based therapies: viewpoints on the way to consensus

Michael A Nauck  1 , Tina Vilsbøll, Baptist Gallwitz, Alan Garber, Sten Madsbad
Affiliations
Review

Incretin-based therapies: viewpoints on the way to consensus

Michael A Nauck et al. Diabetes Care. 2009 Nov.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic diagram explaining the physiological (postprandial) secretion of GLP-1 from the gut, its binding to GLP-1 receptors (e.g., on pancreatic endocrine β-cells), and its degradation by the ubiquitous protease DPP-4 as well as its rapid renal elimination (A). Incretin mimetics are peptide GLP-1 receptor agonists more or less structurally similar to GLP-1, which bind and activate the GLP-1 receptor, but are not degraded by DPP-4 and have much slower elimination pharmacokinetics (B). DPP-4 inhibitors prevent the degradation/inactivation of the biologically active form of GLP-1 and, thereby, augment the biological activity of GLP-1 released from endogenous sources (C).
See this image and copyright information in PMC

References

    1. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696– 1705 - PubMed
    1. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hüfner M, Schmiegel WH: Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239– 1246 - PubMed
    1. Brubaker PL, Drucker DJ: Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004; 145: 2653– 2659 - PubMed
    1. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301– 307 - PMC - PubMed
    1. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665– 673 - PubMed

MeSH terms